Objectives: To determine fusidic acid resistance rates (MICs of ≥2 mg/L) and the prevalence of fusidic acid resistance mechanisms among Staphylococcus spp. collected from European countries (2008).
Introduction
Fusidic acid is an antimicrobial agent isolated from Fusidium coccineum. It has been used in clinical practice in Europe since the early 1960s for the treatment of skin and skin structure infections as well as bone and joint infections caused by Grampositive organisms. 1, 2 Only limited contemporary understanding of fusidic acid resistance at genetic, epidemiological and clinical levels is available, and prescribing practices are mostly based on outmoded data obtained from studies with small numbers of patients. 1 Fusidic acid is able to bind to elongation factor G (EF-G), preventing its release from the ribosome and stalling protein synthesis. Several fusidic acid resistance determinants have been reported to date; however, only recently have most of these mechanisms been characterized. For several years, mutations in fusA, the gene encoding EF-G, were postulated to be the primary cause of resistance against this antimicrobial agent, 2 although strains carrying these mutations were predominantly laboratory mutants that were exposed to fusidic acid. 3 Plasmidmediated resistance has also been described and genes encoding proteins that play a protective role in EF-G were recently identified. 4 The genes encoding these proteins are known as fusB, fusC and fusD, 5 the latter being identified to cause intrinsic fusidic acid resistance among Staphylococcus saprophyticus.
Other mechanisms involved in fusidic acid resistance are mutations in the riboprotein L6 operon within rpIF, which are associated with resistance among small colony variants of Staphylococcus aureus, suggesting that fusidic acid could have a secondary site of action in this ribosomal region. 6 In addition, chloramphenicol acetyltransferase type I found in Enterobacteriaceae species inactivates fusidic acid by competitively binding to this molecule and sequestering it; 2 however, this mechanism does not seem to play an important role in staphylococcal resistance to fusidic acid.
Resistance to fusidic acid was recognized early during the development of this compound; however, despite years of clinical use, resistance rates are considered to be low. 2 In this study, fusidic acid resistance rates and mechanisms of resistance were determined when tested against a large contemporary collection of Staphylococcus spp. collected in European hospitals during 2008.
Materials and methods

Bacterial isolates
During 2008, a total of 3134 staphylococcal isolates collected from 28 European medical sites were analysed in the SENTRY Antimicrobial Surveillance Program. Only one isolate per patient from documented infections was included in the study. Some strains collected in medical centres that had an elevated number of fusidic acid-non-susceptible strains, due to documented clonal occurrences or epidemics, were excluded from the molecular characterizations but not from resistance rate analysis. S. saprophyticus was also excluded because this bacterial species carries fusD, causing intrinsic elevated fusidic acid MIC values. Isolates were collected from bloodstream, respiratory tract and skin structure infections, according to a common protocol. Species identification was confirmed by standard biochemical tests, the Vitek System (bioMérieux, Hazelwood, MO, USA) or 16S rRNA sequencing, when necessary.
Antimicrobial susceptibility testing
All isolates were tested for antimicrobial susceptibility using the broth microdilution method, as described by the CLSI. 7, 8 Cation-adjusted Mueller-Hinton broth was used in validated panels manufactured by TREK Diagnostics (Cleveland, OH, USA). Categorical interpretations for all antimicrobials were those found in M100-S19, 8 and quality control (QC) was performed using Escherichia coli ATCC 25922, S. aureus ATCC 29213 and Pseudomonas aeruginosa ATCC 27853. All QC results were within specified ranges, as published in CLSI documents. 8 
Detection of fusidic acid resistance mechanisms
Isolates displaying a fusidic acid MIC of ≥2 mg/L were tested for the presence of fusB, fusC and fusD in a multiplex PCR approach. 9 Amplification products of 496, 128 and 525 bp were produced with specific oligonucleotides designed for the detection of fusB, fusC and fusD, respectively, and an internal control. 9, 10 At least one amplicon of each type was sequenced and used as a control.
Strains presenting negative results for fusB, fusC and fusD, and/or showing highly elevated fusidic acid MIC values (≥512 mg/L) were evaluated for the detection of mutations in fusA and/or fusE. Amplification was performed with specific primers (Table 1) , and amplicons were sequenced in five and two reactions, respectively. The nucleotide sequences and deduced amino acid sequences were analysed using the Lasergene software package (DNASTAR, Madison, WI, USA) and compared with sequences available through the Internet using BLAST (http://www.ncbi. nlm.nih.gov/blast/). Castanheira et al.
Detection of fusA L461K mutation
A rapid method for evaluation of the L461K mutation in fusA was developed and amplification was performed using four oligonucleotides (Table 1) . Reactions were carried out in 20 mL using Qiagen Multiplex Master Mix (Qiagen, Hilden, Germany), 0.1-0.4 mM of primers and 2 mL of the template. Cycling conditions were initiated by cell denaturation of 15 min at 958C, followed by 35 cycles of 15 s at 948C, 30 s at 508C and 45 s at 728C for denaturing, annealing and extension, respectively, and final extension at 728C for 5 min. PCR products were visualized after 2% agarose gel electrophoresis. Two bands were detected in all strains tested; isolates positive for L461K had one band of 415 bp and another of 145 bp; L461K-negative strains had bands of 415 and 308 bp ( Figure 1 ). Strains harbouring the L461K mutation detected by sequencing and other isolates that did not display this mutation, including S. aureus ATCC 29213, were used to validate this method.
Molecular typing
Isolates were molecular typed by PFGE, as previously described. 11 Results were analysed by GelCompar II software (Applied Math, Kortrijk, Belgium). Percentage similarities were identified on a dendrogram derived from the unweighted pair group method using arithmetic averages and based on Dice coefficients. Band position tolerance and optimization were set at 1.2% and 0.5%, respectively. Isolates showing a similarity coefficient of ≥80% were considered genetically related.
Results
Fusidic acid resistance rates in Europe
Among 3134 staphylococci collected from 28 hospitals in 13 European countries, 443 (14.1%) strains displayed MIC values of ≥2 mg/L for fusidic acid by reference broth microdilution. Overall, 10.7% (288/2700) of the S. aureus displayed fusidic acid MIC values of ≥2 mg/L, whereas 35.7% (155/434) of the coagulase-negative staphylococci (CoNS) strains were nonsusceptible to this antimicrobial agent.
Fusidic acid acquired resistance mechanisms
A total of 336 fusidic acid-non-susceptible strains were selected for further molecular evaluation (multiple representatives of clones were excluded). Approximately 30% (56/191) of the fusidic acid-non-susceptible S. aureus strains evaluated exhibited MICs of ≥64 mg/L, and 48 (85.7%) of these strains were collected in Ireland and Greece. CoNS fusidic acid MIC values were generally lower (,64 mg/L) and these strains were evenly distributed among all 13 countries evaluated. Acquired fusidic acid resistance genes were present in 64.9% (218/336) of the nonsusceptible strains; 123 (36.6%) strains harboured fusB and 95 (28.3%) strains carried fusC. The fusB gene was more prevalent among the CoNS strains compared with S. aureus (26.5% versus 10.1%, respectively; Table 2 ), whereas fusC was similarly detected in both staphylococcal groups (16.9% of CoNS and 11.3% of S. aureus). The majority of strains carrying these acquired genes displayed fusidic acid MIC values of ,64 mg/L.
Mutations in fusA and fusE S. aureus strains that yielded negative PCR results for the presence of acquired fusidic acid resistance genes were selected for the sequencing of fusA and fusE. A total of 62 fusidic acid-non-susceptible strains were amplified and sequenced, and mutations in fusA were detected in 56 (16.6% overall strains) of these. The amino acid alteration L461K was the most frequent, being detected in 32 strains showing fusidic acid MIC values of ≥512 mg/L. Isolates harbouring this mutation were primarily collected in hospitals from Greece and Ireland (27 strains), but were also identified in strains from other countries (Table 2) . Additionally, one strain from Turkey showing a fusidic Fusidic acid resistance mechanisms in Europe acid MIC of 128 mg/L presented L461K alteration associated with two other amino acid substitutions in the fusA product (V90I and H457Q). The second most common type of EF-G amino acid alteration (10 strains) was detected in the same position, but the substitution detected was from leucine to serine (L461S). Strains showing this alteration were detected in Israel, Ireland, Italy, Poland, the UK and France, and displayed lower fusidic acid MIC values (4-8 mg/L) when compared with the strains displaying the substitution L461K.
Other alterations detected in EF-G were H457Y, P404L, A376V, F441Y, V90A, V90I, and the combinations D189V/L430S, T387I/ E449K and A70V/A160V/H457Y (Table 2 ). Amino acid alterations H457Y, P404L and V90I were detected in three, two and two strains, respectively (from different countries), whereas the others were detected in one strain each. Fusidic acid MIC values for these isolates were moderately elevated for most strains (4 -64 mg/L), but one strain showing H457Y substitution had a fusidic MIC of 512 mg/L.
Since the fusA mutation causing the L461K alteration was commonly detected as a cause of resistance in this collection, and was associated with very elevated fusidic acid MIC values, a PCR reaction was developed to allow for the rapid detection of this mutation (Figure 1) . A total of 20 S. aureus strains that had fusA sequenced were tested to validate this method. The results were positive for all 10 strains showing mutations leading to the amino acid change L461K and were negative for those strains carrying different or no mutations, including strains with the L461S substitution. Additionally, 14 S. aureus strains showing fusidic acid MIC values of ≥1024 mg/L were tested using this method and all displayed positive results for the mutation causing the L461K alteration in EF-G. These strains were collected in hospitals located in Ireland and Greece.
Among nine isolates tested for the detection of fusE mutations, only one strain from Ireland showed an amino acid alteration in ribosomal protein L6 (Q140L; Table 2) not described in previous studies. This strain did not demonstrate a small colony variant morphology, but displayed a fusidic acid MIC of 16 mg/L. The role of this L6 N-terminal mutation in fusidic acid resistance needs to be further evaluated.
Geographical differences in fusidic acid resistance mechanisms
Strains from different countries showed remarkable differences in the fusidic acid resistance rates and occurrences of resistance mechanisms for CoNS and S. aureus (Table 2) . Among 18 fusidic acid-resistant strains from Belgium, all 12 CoNS carried fusB or fusC, whereas for 6 S. aureus only 1 carried acquired genes. Four of the remaining S. aureus strains showed low MIC results (2 -8 mg/L) and fusA mutations were detected in two of the three strains tested, including one isolate with a highly elevated fusidic acid MIC value (512 mg/L). Strains from five French medical sites were analysed and the majority harboured acquired genes (52/70 tested strains, 74.3%). CoNS from France carried fusB (28/38 strains), whereas S. aureus possessed fusC (16/32). Eighteen S. aureus strains did not carry acquired resistance genes and, among these, 10 were screened for mutations in the fusA gene. Six types of single or multiple amino acid substitutions were detected in nine S. aureus (3) - (2) France ( (10) - (1) Germany ( (3) - (1) Greece ( (1) - (1) Turkey ( Castanheira et al.
strains and the L461S alteration was characterized in four strains, with two showing different PFGE patterns. Two-thirds of the fusidic acid-resistant strains collected in German hospitals were CoNS (23 out of 36 strains); 7 and 8 of these strains carried fusB and fusC, respectively. Overall, most isolates from German hospitals had modestly elevated fusidic acid MIC values (4 -64 mg/L) and only two strains showed highly resistant MIC values (512-1024 mg/L). One of these two strains was an S. aureus carrying the H457Y EF-G alteration and one was an Staphylococcus epidermidis displaying the L461K substitution.
There was a high prevalence of fusidic acid resistance in Greece (62.4%) and 42 consecutive strains from this country were analysed overall. Most of the fusidic acid-non-susceptible strains from Greece were S. aureus showing high-level MIC values (≥512 mg/L) and the fusA L461K mutation was detected in all 10 strains tested. PFGE showed the presence of one major clone in each surveyed hospital (clusters of six and three strains) among the highly resistant strains harbouring the L461K substitution. S. aureus and one CoNS strain tested showing lower MIC results (8-16 mg/L) harboured fusB. A similar scenario was observed in Ireland, although fusidic acid resistance rates were considerably lower (19.9%) than in Greece. Most strains were S. aureus with very high fusidic acid MIC values associated with negative tests for acquired genes. The EF-G L461K alteration was detected in 17 of 21 fusidic acid-resistant Irish strains tested. Additionally, one strain showed fusA mutations D189V and L430S, and another had the fusE mutation Q140L. PFGE analysis demonstrated the presence of clones harbouring fusA mutations in each of the two participant hospitals (four and nine strains identified) and one cluster was found in both institutions (four strains).
Low rates (1.4%-3.1%) of fusidic acid resistance in S. aureus were detected in Israel, Italy, Poland, Spain and Sweden (Table 2) when compared with other countries. These rates were slightly higher in Switzerland, Turkey and the UK (6.3%-11.8%). The majority of the strains recovered in these countries exhibited MIC values of ≤64 mg/L and great diversity in the prevalence of fusidic acid resistance mechanisms was demonstrated ( Table 2) .
Discussion
Since the early 1970s, the horizontal acquisition of genes has been postulated to be the main mechanism encoding fusidic acid resistance in S. aureus clinical strains, 12 despite early studies suggesting that alterations in EF-G were the primary fusidic acid resistance mechanism detected in laboratory mutants. More recently, McLaws et al. suggested that among acquired resistance genes fusB was the most prevalent mechanism in S. aureus and S. epidermidis clinical strains. 12 In this study, we evaluated a broad contemporary European collection of staphylococcal strains, and fusC was noted to be very prevalent among CoNS and S. aureus; furthermore, this gene was more prevalent than fusB among S. aureus strains showing elevated fusidic acid MIC values (16.9% and 10.1%, respectively).
In a recent study, fusA mutations were demonstrated to be as frequently detected as the presence of fusB and fusC among invasive S. aureus strains in hospitals from Denmark. 3 In contrast, the rate of acquired fusidic acid resistance genes (56.9% of the fusidic acid-resistant strains) detected among S. aureus recovered from blood cultures (44.1% of included isolates) in the present study was higher than that of FusA mutation. Moreover, most strains carrying no acquired fusidic acid resistance genes were clonal occurrences in a limited number of hospitals, mostly located in two countries, Greece and Ireland. Over 30 fusA mutation-types have been described in the literature 3 and only a few of these mutations were actually experimentally confirmed as the cause of fusidic acid resistance. 13 Among the amino acid changes associated with fusidic acid resistance, L461K was previously reported as prevalent among clinical strains with high levels of fusidic acid resistance. In addition, S. aureus strains carrying this mutation were described to be polyclonal. 13 The substitution L461K results in higher fusidic acid resistance levels compared with other alterations in the same positions (L461S and L461F). 13, 14 These prior observations corroborate the results of the present study, confirming that L461K is frequently observed in clinical strains showing highly elevated fusidic acid MIC values. Additionally, we also observed that although frequently detected, L461S is associated with lower fusidic acid MIC values.
Among other EF-G alterations observed in this study, substitutions at position 457 (H457Y and H457Q) were previously described to be present in clinical strains and these substitutions along with those detected in amino acid 461 were considered important for in vivo resistance. 13 Furthermore, the EF-G alterations V90I and V90A generated fusidic acid MIC rates of 4 mg/L, indicating a role in resistance.
Mutation A376V, encoding EF-G protein alteration, was detected in the present study and was previously described to be associated with a compensatory alteration to overcome slow cell growth.
14 However, since this strain had an MIC value of 32 mg/L and no other resistance determinant was detected, this alteration alone could have a modest role in fusidic acid resistance that was previously masked by a mutation encoding higher resistance levels. The strains harbouring multiple EF-G amino acid substitutions showing low fusidic acid MIC values may have additional compensatory mutations and/or have polymorphisms that are not related to fusidic acid resistance. 14 These compensatory mutations may overcome the loss of fitness cost due to the mutations causing resistance. 13 The vast majority of the strains evaluated here had slightly elevated MIC values (2-64 mg/L), which is in agreement with prior observations, indicating that the protective interaction of FusB-type proteins in EF-G results in low MIC levels (4-16 mg/L). 3 Conversely, strains with the fusA L461K amino acid substitution (most strains displaying multiple fusA mutations) showed a highly elevated fusidic acid MIC (≥256 mg/L).
Recent studies described the presence the European fusidic acid-resistant impetigo clone (EEFIC) in the UK, Ireland and France. 15 This clonal S. aureus strain, which is also described in Scandinavia and sporadically reported in other countries, is characterized by (i) agr allelic group IV, (ii) spa type 171 (or single locus variants t408, t659, t874 and t875), (iii) sequence type 123 (clonal complex 121), (iv) the presence of exfoliative toxin A (etaA) and often etaB; (v) low levels of fusidic acid resistance due to the presence of chromosomal fusB and (vi) strong association with impetigo. 16, 17 In the present study, several S. aureus strains harbouring fusB were detected. The majority of these were Fusidic acid resistance mechanisms in Europe collected from blood cultures, but small numbers were collected from skin infections or wounds of hospitalized patients. Four fusBcarrying strains recovered from these infection sites were spa typed to investigate the correlation with EEFIC. These strains, isolated in French, Irish and British hospitals, displayed spa types t261, t189, t1546 and the novel variant t5876, being unrelated to the clonal EEFIC strain. These results may indicate a recent decrease in the prevalence of the EEFIC clone or a low number of impetigo-like cutaneous infections that were received from hospital-based laboratories in this survey.
The need for epidemiological data on fusidic acid resistance mechanisms has been recently highlighted by other authors 1, 12 and although there has been an increase in the understanding of these genetic determinants over the last 2 years, only data from small sample subsets are currently available in the medical microbiology literature. In this study, however, we evaluated a large collection of staphylococcal strains using a strategy that minimized the cost of molecular surveillance. All strains were tested for the presence of acquired fusidic acid resistance genes (fusB, fusC and fusD), and only those lacking these genes were molecular typed and evaluated for the presence of fusA and fusE mutations. This approach is supported by the observation from O'Neill and Chopra 4 that the insertion of fusB in isolates already carrying fusA mutations did not increase fusidic acid resistance levels, indicating that the combination of mechanisms offers no clear advantage to the bacterial cell and therefore would rarely emerge in clinical strains. 4 Additionally, a rapid method for the identification of the alteration L461K was developed to optimize the detection of this prevalent substitution, which encodes high-level fusidic acid resistance. This strategy allowed us, and hopefully will allow other researchers, to produce epidemiologically and clinically significant therapeutic information.
Fusidic acid has been used for the treatment staphylococcal infections in European countries for nearly 50 years. Overall, resistance rates in most countries surveyed during this study remain at low levels, contradicting the early beliefs that widespread fusidic acid resistance would rapidly emerge after the clinical availability of this compound. 2 The elevated fusidic acid resistance rates observed in certain countries (Greece and Ireland) with a concurrent high prevalence of fusA mutations may indicate a distinct usage pattern of this antimicrobial agent that exerts higher selective pressure, causing mutations to arise followed by clonal expansion.
